RecruitingNot ApplicableNCT06618599

Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block

Analgesic Effect of Mid-transverse Process to Pleura Block Combined With Erector Spinae Block Versus Paravertebral Plane Block in Thoracic Surgery for Lung Cancer Patients


Sponsor

Cairo University

Enrollment

60 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare efficacy of Mid-transverse process to pleura block combined with erector spinae block versus paravertebral plane block in cancer patients undergoing thoracotomy surgeries.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This trial is comparing two different regional nerve block techniques — a mid-transverse process to pleura (MTP) block combined with an erector spinae plane (ESP) block versus a paravertebral plane (PVP) block — for pain control in patients undergoing thoracotomy (open chest surgery) for lung cancer. The goal is to find which nerve block approach better manages pain after surgery. **You may be eligible if...** - You are a lung cancer patient between 18 and 65 years old scheduled for thoracotomy (open chest surgery) - Your BMI is between 20 and 35 kg/m² - Your overall health status is classified as moderate risk (ASA II or III) **You may NOT be eligible if...** - You refuse participation - Your overall health is too poor (ASA IV) - You are under 18 or over 65 years old - You have a known allergy to local anesthetics or opioids used in the study - You have a history of chronic pain or psychological disorders - You have conditions that make regional anesthesia unsafe (infection, nerve disorders, clotting problems) - You have severe heart, lung, liver, or kidney disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMid-transverse process to pleura block combined with erector spinae block

The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected

PROCEDUREparavertebral block

the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06618599


Related Trials